Editas Medicine's Progress in Inherited Retinal Disease Gene Editing Highlighted
For those in the inherited retinal disease (IRD) community, advancements in gene editing therapies offer significant hope. A recent article from The Motley Fool, published on January 26, 2021, shed light on the progress of Editas Medicine, a company at the forefront of CRISPR-based gene editing, particularly their work on a potential treatment for Leber Congenital Amaurosis (LCA).
The article, titled "Is Editas Medicine a Buy?", specifically discusses EDIT-101, Editas Medicine's lead clinical program. This therapy is designed to treat Leber Congenital Amaurosis type 10 (LCA10), a severe form of inherited childhood blindness. What makes EDIT-101 particularly notable is its method: it is an in vivo CRISPR gene editing medicine. This means the gene editing is intended to occur directly inside the patient's body, rather than cells being modified outside the body and then re-introduced.
According to The Motley Fool, EDIT-101 was the first in vivo CRISPR gene editing medicine to be dosed in a human clinical trial. This milestone, achieved in 2020, marked a significant step forward in the application of CRISPR technology for genetic diseases. The article notes that the trial for EDIT-101 is known as BRILLIANCE.
The initial focus of the BRILLIANCE trial was on patients with advanced LCA10, who had very little vision. The Motley Fool reported that the trial was designed to evaluate the safety and efficacy of EDIT-101 in these individuals. The company's strategy, as reported, was to first assess the treatment in patients with limited vision, and then potentially expand to those with more remaining vision if the initial results were promising.
For patients and families affected by LCA10 and other IRDs, this news underscores the ongoing dedication to finding transformative treatments. The development of in vivo gene editing therapies like EDIT-101 represents a cutting-edge approach that could one day offer a new path for managing or even reversing the effects of inherited retinal diseases. While these are early stages, the initiation of human trials for such an innovative therapy is a crucial step forward.
Looking ahead, the progress of clinical trials such as BRILLIANCE will continue to be closely watched by the IRD community. The insights gained from these studies are vital for understanding the potential of gene editing to address genetic causes of blindness and improve the lives of those living with these conditions.